Compare Abeona Therapeutics Inc (ABEO) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Chevron Corp — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Chevron Corp trades at $175.92 (market cap $346.56B). The key difference: Chevron Corp is far larger — about 928.3× Abeona Therapeutics Inc's market cap, and Chevron Corp pays a 4.09% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CVX | |
|---|---|---|
Market Cap | $373.32M | $346.56B |
Sector | Health | Energy |
52-Week High | $7.23 | $211.14 |
52-Week Low | $4.17 | $146.72 |
Enterprise Value | $228.22M | $386.66B |
Volume | — | 9,807,834 |
Dividend Yield | — | 4.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Chevron (CVX) trades at $168.1, down 0.66% on the day, amid a broader technical bearish signal. The stock shows mixed fundamentals with declining revenue and net income over recent years, though it has consistently beaten earnings expectations. A strong $1.78 dividend is scheduled for payment in June 2026. Wall Street sentiment remains predominantly bullish, with a consensus price target of $209 representing significant upside, countering the current technical weakness.
The investment case balances a high analyst buy rating and attractive dividend against fundamental profit margin compression and exposure to volatile oil prices. Key risks include execution of major projects like the $13.8B Argentina investment and geopolitical tensions affecting supply chains. The stock's current price sits near immediate technical support at $167.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
